Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 13, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 675,000 ordinary shares of 25 pence each.
- Purchase Price: 1,434.34 pence per share.
- Treasury Holdings: Following the purchase, the company holds 261,772,678 shares in Treasury.
- Shares in Issue: 5,747,674,109 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 675,000 shares on March 13, 2007. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the standard disclosure that the announcement does not constitute an offer to purchase securities. The transaction is noted as being in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (261,772,678) against subsequent filings to track ongoing buyback activity.
- Confirm the total voting rights denominator (5,747,674,109) for calculating disclosure thresholds under Financial Services Authority rules.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share repurchase authority utilized.